Although immune checkpoint inhibitors (ICIs) can improve the treatment landscape of NSCLC without EGFR, ALK or ROS1 aberrations, and reduce the proportion of chemotherapy in patients with high PD-L1 expression, leading to that these patients can avoid chemotherapy-related complications toxicity, the overall survival benefits still require to be improved by combination therapy (Huang et al., 2021). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.